D. Benziger

发表

D. Benziger, J. Edelson, 1983, Drug metabolism reviews.

Use of WIN 51711 to prevent echovirus type 9-induced paralysis in suckling mice.

M. Mckinlay, D. Benziger, J. Frank, 1986, The Journal of infectious diseases.

Clinical Pharmacokinetics of Controlled‐Release Oxycodone in Renal Impairment

D. Benziger, R. Kaiko, C. Cheng, 1996 .

Pharmacokinetics and Tolerability of Daptomycin at Doses up to 12 Milligrams per Kilogram of Body Weight Once Daily in Healthy Volunteers

S. Yankelev, D. Benziger, M. Benvenuto, 2006, Antimicrobial Agents and Chemotherapy.

Chapter 29. Drug Metabolism

D. Benziger, J. Edelson, J. E. Peterson, 1981 .

Pharmacokinetic‐pharmacodynamic relationships of controlled‐release oxycodone

R. Reder, P. Goldenheim, R. Fitzmartin, 1996, Clinical pharmacology and therapeutics.

Analysis of cyclazocine in plasma.

D. Benziger, J. Edelson, J. E. Peterson, 1979, Journal of pharmaceutical sciences.

A pilot study of high‐dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram‐positive bacteria

K. Lindfield, W. Martone, J. Steenbergen, 2008, International journal of clinical practice.

Pharmacokinetics of the bipyridines amrinone and milrinone.

R. Cody, W. Hood, K. Chatterjee, 1986, Circulation.

The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient adults.

L. Phillips, A. Hoffman, M. Vance, 2002, The Journal of clinical endocrinology and metabolism.

Absorption and disposition of 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid, WIN 35,833, in rats, monkeys, and men.

A. Fritz, D. Benziger, J. Edelson, 1975, Drug metabolism and disposition: the biological fate of chemicals.

Relative bioavailability and pharmacokinetics: a combination of pentazocine and acetaminophen.

A. Fritz, D. Benziger, J. Edelson, 1984, Journal of pharmaceutical sciences.

Quinolone and “Azaquinolone” Antimicrobial Agents

D. Benziger, J. Edelson, C. Davison, 1977 .

Clinical and pharmacokinetic considerations for the use of daptomycin in patients with Staphylococcus aureus bacteraemia and severe renal impairment.

A. Chakraborty, S. Tannenbaum, R. Chaves, 2014, The Journal of antimicrobial chemotherapy.

Subchronic Oral and Intravenous (iv) Safety Evaluation and Pharmacokinetics in Rats and Dogs of Ipazilide Fumarate (Win 54, 177-4), an Antiarrhythmic Agent

T. Barbolt, J. Dean, B. Mayes, 1992 .

Pharmacokinetics and safety of multiple doses of daptomycin 6 mg/kg in noninfected adults undergoing hemodialysis or continuous ambulatory peritoneal dialysis.

S. Swan, S. Yankelev, P. Pertel, 2011, Clinical nephrology.

Metabolism of amrinone in animals.

D. Benziger, J. Edelson, J. F. Baker, 1982, Drug Metabolism And Disposition.

Chapter 33. Drug Metabolism

J. Baker, D. Benziger, J. Edelson, 1982 .

Role of hepatic glycogenolytic enzymes in the cold-induced hyperglycemia of the killifish, Fundulus heteroclitus.

D. Benziger, B. L. Umminger, 1973, Comparative biochemistry and physiology. A, Comparative physiology.

High-performance liquid chromatographic assay for hydroxychloroquine and three of its major metabolites, desethylhydroxychloroquine, desethylchloroquine and bidesethylchloroquine, in human plasma.

R. Brown, R. Stroshane, Richard R. Brown, 1986, Journal of chromatography.

Disposition of a series of tetrahydrocarbazoles.

D. Benziger, J. Edelson, Jerome Edelson, 1980, Drug metabolism reviews.

Pharmacokinetics and Safety of Intravenous Ceftolozane-Tazobactam in Healthy Adult Subjects following Single and Multiple Ascending Doses

E. Hershberger, I. Friedland, D. Benziger, 2012, Antimicrobial Agents and Chemotherapy.

Metabolism and disposition of amifloxacin in laboratory animals

D. Benziger, J. Johnson, 1985, Antimicrobial Agents and Chemotherapy.

Analysis of amifloxacin in plasma and urine by high-pressure liquid chromatography and intravenous pharmacokinetics in rhesus monkeys

L. McCoy, D. Benziger, B. P. Crawmer, 1985, Antimicrobial Agents and Chemotherapy.

The effect of pH and cold acclimation upon glucose-6-phosphatase activity in the goldfish, Carassius auratus

D. Benziger, B. L. Umminger, 1974 .

In vitro stimulation of hepatic glycogen phosphorylase activity by epinephrine and glucagon in the brown bullhead, Ictalurus nebulosus.

D. Benziger, B. L. Umminger, 1975, General and comparative endocrinology.

In vitro stimulation of hepatic glycogen phosphorylase activity by epinephrine and glucagon in the killifish, Fundulus heteroclitus.

D. Benziger, B. L. Umminger, S. Levy, 1975, Comparative biochemistry and physiology. C: Comparative pharmacology.

Dosing strategy to allow continued therapy with daptomycin after asymptomatic increases in creatine kinase levels.

H. N. Patel, S. Burdette, D. Benziger, 2014, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Single-Dose Pharmacokinetics of Daptomycin in Children With Suspected or Proved Gram-Positive Infections

H. Jafri, G. Kearns, R. Jacobs, 2008, The Pediatric infectious disease journal.

Nephrotoxicity of pravadoline maleate (WIN 48098-6) in dogs: evidence of maleic acid-induced acute tubular necrosis.

J C Bradford, S. Ward, R M Everett, 1993, Fundamental and applied toxicology : official journal of the Society of Toxicology.

Differential effects of food on the bioavailability of controlled-release oxycodone tablets and immediate-release oxycodone solution.

M. Chasin, R. Reder, R. Fitzmartin, 1996, Journal of pharmaceutical sciences.

Disposition of trilostane in the rat and monkey.

L. Shargel, A. Fritz, D. Benziger, 1980, Archives internationales de pharmacodynamie et de therapie.

A pharmacokinetic/pharmacodynamic study of controlled-release oxycodone.

R. Fitzmartin, D. Benziger, R. Swanton, 1997, Journal of pain and symptom management.

Disposition of arildone, an antiviral agent, after various routes of administration

D. Benziger, J. Edelson, 1982, Antimicrobial Agents and Chemotherapy.

Effect of the acetylator phenotype on amrinone pharmacokinetics

R. Hamilton, S. Kowalsky, R. Stroshane, 1986, Clinical pharmacology and therapeutics.

Blood levels, tissue distribution and the duration of action in rats of ciprofibrate, a new hypolipidemic agent.

D. Benziger, J. Edelson, A. Arnold, 1979, Atherosclerosis.

Plasma pentazocine radioimmunoassay.

D. Benziger, J. Edelson, J. E. Peterson, 1979, Journal of pharmaceutical sciences.

Single-dose Pharmacokinetics of Daptomycin in Pediatric Patients 3–24 Months of Age

R. Jacobs, P. Bokesch, J. Bradley, 2014, The Pediatric infectious disease journal.

Single-dose Pharmacokinetics and Tolerability of Daptomycin 8 to 10 mg/kg in Children Aged 2 to 6 Years With Suspected or Proved Gram-positive Infections

R. Jacobs, S. Abdel‐Rahman, J. Bradley, 2011, The Pediatric infectious disease journal.

Pharmacokinetics (PK) and Safety of 8 and 10 mg/kg of Daptomycin in Pediatric Patients Aged 2 to 6 Years

D. Benziger, 2009 .

The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient adults.

L. Phillips, M. Vance, A. Illeperuma, 2002, The Journal of clinical endocrinology and metabolism.